IGF-1 LR3
IGF-1 analog. IGF-1 LR3 is not FDA approved for any use.
Key facts
- Class
- IGF-1 analog
- Also called
- LR3
- Vial sizes sold
- 0.1 mg, 1 mg
- Community-reported sizes
- Half-life
- 563 min half-life in wound fluid (versus 872 min for IGF-I)
- wound chamber (rat), rat · The American journal of physiology 1999, PMID 10198302
- FDA status
- Not approved
- research chemical
- WADA
- Prohibited (S2.3)
- In and out of competition
IGF-1 LR3 guides
Evidence at a glance
Human and animal counts are PubMed records from our evidence ledger (search counts, not studies we reviewed). The grade is the strongest design among the studies we summarised for that goal: a human randomized trial outweighs any number of animal studies.
| Condition | Human studies | Animal studies | Studies we summarised | Evidence grade |
|---|---|---|---|---|
| Muscle growth | 0 | 6 | 8 | Animal evidence, 2 of 4American journal of physiology. Endocrinology and metabolism 2025, PMID 39679943 |
| Weight loss | Not in our ledger | Not in our ledger | 0 | No graded study for this goal |
Grades follow our evidence scale. Summarised studies come from our evidence file, each quote checked against the abstract or label.
Long R3 IGF-I: a modified IGF-I with no human trials found
The only paper involving people is an analysis of a black-market vial. It states that the effects of the modified peptide in humans have not been elucidated or described.[4]
In diabetic rats, the variants were 2.5-3 times more potent than IGF-I at restoring growth. This is animal data.[11]
Mixed animal results
In guinea pigs, a short infusion enlarged some organs but did not stimulate overall growth.[12]
In pigs, a short infusion decreased average daily gain, food intake and plasma IGF-I.[13]
In tumour-bearing rats, tumour growth was increased by the IGFs, especially LR3-IGF-I, even though the peptides did not promote growth of the adenocarcinoma in cell culture.[14]
In growth-restricted fetal sheep, a 1-week course of treatment did not improve growth.[3]
Regulatory path
The Drugs@FDA search for IGF-1 LR3 returned no match.[2]
WADA's S2.3 prohibits IGF-1 and its analogues; LR3 is a modified IGF-I.[1]
Compared with
Common stacks
IGF-1 LR3 is often sold pre-mixed or combined with other peptides. No controlled study has tested these combinations; the pages below cover the math and what each part has been studied for.
Common questions
Is IGF-1 LR3 FDA approved?
No. IGF-1 LR3 is not FDA approved for any use.
Is IGF-1 LR3 banned in sport?
Yes. Prohibited by WADA (S2.3), so it is prohibited at all times for tested athletes.
How much water goes in a 1 mg vial?
That choice only changes the concentration. With 2 mL, the vial is 0.5 mg/mL. The calculator converts any amount to syringe units. It does the math only and does not suggest a dose.
What is IGF-1 LR3?
A modified form of IGF-I; the cached studies are in animals, plus one analysis of a black-market vial.[11]
What does IGF-1 LR3 do?
Animal results are mixed: it increased growth in some models and not in others. No human trial was found.[12]
What is the half-life of IGF-1 LR3?
The only value is from rat wound fluid, where half-life was 563 minutes versus 872 for IGF-I; this is not a human figure.[5]
Sources
- 1World Anti-Doping Code International Standard Prohibited List 2026World Anti-Doping Agency · 2026wada-ama.orgAccessed 2 Oct 2026
- 2United States: No FDA-approved product found: Drugs@FDA (openFDA) search for active ingredient "IGF-1 LR3" returned no matches on 2 Oct 2026.U.S. Food and Drug Administration · 2026api.fda.govAccessed 2 Oct 2026
- 3IGF-1 LR3 does not promote growth in late-gestation growth-restricted fetal sheep.American journal of physiology. Endocrinology and metabolism · 2025PMID 39679943Accessed 2 Oct 2026
- 4Detection of His-tagged Long-R³-IGF-I in a black market product.Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society · 2010PMID 20675162Accessed 2 Oct 2026
- 5Clearance of IGFs and insulin from wounds: effect of IGF-binding protein interactions.The American journal of physiology · 1999PMID 10198302Accessed 2 Oct 2026
- 6PubMed search: ("Long R3"[tiab] OR (LR3[tiab] AND (IGF[tiab] OR "IGF-1"[tiab] OR "IGF-I"[tiab] OR "insulin-like growth factor"[tiab]))) (109 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 7PubMed search: ("Long R3 IGF-I"[tiab] OR "LR3 IGF-I"[tiab] OR "IGF-I LR3"[tiab] OR "LR3-IGF-I"[tiab] OR "IGF-1 LR3"[tiab] OR "LR3 IGF-1"[tiab] OR "[Long R3]IGF-I"[tiab]) AND (rat[tiab] OR rats[tiab] OR mice[tiab] OR infusion[tiab] OR muscle[tiab] OR pigs[tiab] OR in vivo[tiab]) (38 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 8PubMed search: "long R3 IGF"[tiab] OR "long-R3 IGF"[tiab] OR "LR3-IGF"[tiab] OR "LR3 IGF"[tiab] OR "R3 IGF-I"[tiab] (95 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 9PubMed search: ("LR3"[tiab] AND IGF[tiab]) AND (half-life[tiab] OR pharmacokinetic*[tiab] OR clearance[tiab]) (2 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 10PubMed search: ("Long R3"[tiab] OR "IGF-1 LR3"[tiab] OR "LR3 IGF"[tiab] OR "LR3-IGF"[tiab]) AND (adverse[tiab] OR "side effect*"[tiab] OR safety[tiab] OR tolerab*[tiab] OR toxicity[tiab] OR "case report"[pt]) (2 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 11 Oct 2026
- 11Insulin-like growth factor-I and more potent variants restore growth of diabetic rats without inducing all characteristic insulin effects.The Biochemical journal · 1993PMID 7683875Accessed 2 Oct 2026
- 12Long R3 insulin-like growth factor-I (IGF-I) infusion stimulates organ growth but reduces plasma IGF-I, IGF-II and IGF binding protein concentrations in the guinea pig.The Journal of endocrinology · 1995PMID 7561636Accessed 2 Oct 2026
- 13Long [R3] insulin-like growth factor-I reduces growth, plasma growth hormone, IGF binding protein-3 and endogenous IGF-I concentrations in pigs.The Journal of endocrinology · 1997PMID 9488001Accessed 2 Oct 2026
- 14Effects of insulin and insulin-like growth factors on protein and energy metabolism in tumour-bearing rats.The Biochemical journal · 1994PMID 8053901Accessed 2 Oct 2026
Found an error? Report a correction.